BioSpace News Archive

Dificid is a macrolide antibiotic that was previously approved for CDAD in adults.

It was founded in 1982, almost forty years ago, and doesn’t have a commercial product on the market. But that appears likely to soon change.

As AbbVie and Allergan near completion of the $63 billion merger, the two companies are shedding some assets in order to meet demands of regulators over concerns of a monopoly.

The Chinese government is turning to a drug developed by AbbVie for HIV patients as a potential treatment for the outbreak.

The company announced it had rejected the bid, saying that it “significantly undervalues Sorrento and is not in the best interest of the Company’s stockholders.”

Let’s look at a few ways inclusion and diversity positively impact organizational performance.

You can’t necessarily hand out cash every time something goes right. Instead, you may have to get creative and think outside the box.

In addition to various deal news, AstraZeneca had clinical trial news today as well.

The new network is a global program of collaborations with academic institutions.

Corium, Inc., a commercial-stage biopharmaceutical company leading the development of novel transdermal healthcare products that are intended to provide alternative treatment options for patients and their families, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for ADLARITY (donepezil transdermal system)